Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years

MeSH terms

• Animals
• Drug Approval* / legislation & jurisprudence
• Drug Approval* / organization & administration
• Filaricides / pharmacology
• Humans
• Neglected Diseases / drug therapy*
• Neglected Diseases / parasitology
• Onchocerca / drug effects
• Onchocerca / physiology
• Onchocerciasis, Ocular / drug therapy*
• United States
• United States Food and Drug Administration